AMX-3009 Maleate

Phase Ib: Main purpose: To evaluate the safety and tolerability of AMX3009 in the treatment of patients with locally advanced or metastatic non-small cell lung cancer (rare EGFR mutations) and determine the recommended dose (RP2D) for Phase II clinical trials Phase II: Main purpose: Objective response rate (ORR) of AMX3009 in the treatment of patients with locally advanced or metastatic non-small cell lung cancer (rare EGFR mutations). Secondary objectives: To evaluate the effectiveness of AMX3009 in the treatment of patients with locally advanced or metastatic non-small cell lung cancer (rare EGFR mutations) (including progression-free survival (PFS), overall survival (OS), duration of response (DOR), disease control rate (DCR), etc.); To evaluate the adverse reactions, serious adverse events, physical examination, vital signs, laboratory tests, 12-lead electrocardiogram, echocardiogram, etc. of AMX3009 in patients with locally advanced or metastatic non-small cell lung cancer (rare EGFR mutations); To evaluate the pharmacokinetic (PK) characteristics of AMX3009 in patients with locally advanced or metastatic non-small cell lung cancer (rare EGFR mutations).